Top 10 Companies in the Global Oligosaccharides in Infant Nutrition Market (2026): Market Leaders Powering Infant Nutrition

MARKET INSIGHTS

Global oligosaccharides in infant nutrition market was valued at USD 2.16 billion in 2024 and is projected to reach USD 3.83 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period (2025–2032). This steady expansion reflects growing parental awareness about nutritional benefits and rising demand for premium infant formula products worldwide. While developed markets continue to lead adoption, emerging economies are accelerating growth due to increasing disposable incomes.

Oligosaccharides in infant nutrition are specialized short‑chain carbohydrates designed to mimic human milk oligosaccharides (HMOs), which are crucial for developing gut microbiota and immune function in infants. These ingredients are primarily incorporated into infant formula but also find applications in pediatric nutritional supplements and medical foods. The market focuses extensively on product safety and efficacy, with manufacturers investing heavily in clinical research to validate health claims.

Recent industry developments include technological advancements in fermentation processes that enable cost‑effective production of complex oligosaccharides. Leading manufacturers are expanding their production capacities to meet the growing demand, particularly in Asia‑Pacific where birth rates remain high. The market remains highly regulated across regions, with stringent quality controls governing product formulations and labeling.

Global Oligosaccharides in Infant Nutrition Market – View in Detailed Research Report

Top 10 Companies in the Global Oligosaccharides in Infant Nutrition Market (2026)

1. Abbott Laboratories

Headquarters: Abbott Park, Illinois, USA
Key Offering: Human Milk Oligosaccharide (HMO) fortified infant formulas (Similac™ HMO)
Product Overview: Abbott’s HMO line includes 2‑fucosyllactose (2‑FL) and lacto‑N‑neotetraose (LNnT) blends that replicate the prebiotic profile of breast milk, supporting infant gut microbiota and immune development. The formulations are available in powder and ready‑to‑mix formats for infant nutrition manufacturers worldwide.

Sustainability & Growth Initiatives: Abbott has invested USD 450 million in HMO production facilities and is expanding its fermentation capacity in India and Brazil to meet rising demand in emerging markets.

• Clinical validation of gut microbiome modulation in infants
• Strategic partnerships with regional formula manufacturers
• Commitment to carbon‑neutral production by 2035

2. DuPont Nutrition & Health

Headquarters: Wilmington, Delaware, USA
Key Offering: Galacto‑oligosaccharide (GOS) and fructo‑oligosaccharide (FOS) prebiotic blends for infant formulas and nutritional supplements
Product Overview: DuPont’s prebiotic portfolio enhances infant gut health and supports immune function. The blends are available in powder form for direct use in infant formula manufacturing.

Sustainability & Growth Initiatives: DuPont is scaling its fermentation plants in the EU and Asia‑Pacific, targeting a 30% reduction in CO₂ emissions per kilogram of product by 2030.

• Investments in microbial fermentation technology
• Partnerships with pediatric nutrition experts
• Development of low‑cost GOS variants for emerging markets

3. FrieslandCampina Domo

Headquarters: Domo, Netherlands
Key Offering: GOS‑based prebiotic formulas for infant nutrition and nutraceuticals
Product Overview: FrieslandCampina’s GOS blends are formulated to mimic the gut‑protective properties of HMOs, supporting infant immunity and growth.

Sustainability & Growth Initiatives: The company is expanding its sustainable sourcing of raw materials and has a goal to achieve 100% renewable energy in its production facilities by 2035.

• Innovation in GOS synthesis via engineered yeast strains
• Collaboration with local dairy cooperatives in India
• Launch of premium infant formulas in Brazil and Mexico

4. Ingredion Incorporated

Headquarters: Chicago, Illinois, USA
Key Offering: Advanced carbohydrate processing for GOS, FOS, and inulin blends in infant nutrition
Product Overview: Ingredion’s technology enables high‑purity oligosaccharide production at commercial scale, reducing cost and improving product consistency.

Sustainability & Growth Initiatives: Ingredion is investing in circular bio‑economy projects, converting agricultural by‑products into high‑value oligosaccharides.

• R&D focus on next‑generation prebiotics
• Partnerships with formula manufacturers in Asia‑Pacific
• Carbon‑neutral manufacturing goal by 2035

5. Carbosynth

Headquarters: Watford, United Kingdom
Key Offering: Custom oligosaccharide synthesis for infant nutrition and medical foods
Product Overview: Carbosynth offers bespoke 2‑FL, LNnT, and GOS solutions tailored to client specifications, supporting premium formula development.

Sustainability & Growth Initiatives: The company is expanding its biocatalytic platforms to reduce solvent use and improve process efficiency.

• On‑demand oligosaccharide synthesis services
• Collaborations with academic research institutions
• Targeted growth in North America and Europe

6. Inbiose NV

Headquarters: Ghent, Belgium
Key Offering: Microbial fermentation of GOS and FOS for infant nutrition
Product Overview: Inbiose’s engineered yeast strains produce high‑purity GOS and FOS, supporting infant gut health.

Sustainability & Growth Initiatives: Inbiose is focusing on low‑energy fermentation processes and is expanding its production capacity in Eastern Europe.

• Innovation in strain development
• Strategic alliances with formula manufacturers
• Commitment to circular bio‑economy principles

7. Jennewein Biotechnologie GmbH

Headquarters: Weiden, Germany
Key Offering: Microbial fermentation of HMOs, including 2‑FL and LNnT
Product Overview: Jennewein’s technology enables scalable production of complex HMOs, positioning the company as a technology leader in the market.

Sustainability & Growth Initiatives: The firm is investing in renewable energy for its fermentation facilities and collaborating with universities for advanced HMO research.

• Large‑scale HMO production capacity
• Partnerships with pediatric nutrition experts
• Expansion into emerging markets via joint ventures

8. Tereos

Headquarters: Orléans, France
Key Offering: GOS and FOS blends for infant nutrition and functional foods
Product Overview: Tereos provides high‑quality oligosaccharide blends that support infant gut microbiota and immune function.

Sustainability & Growth Initiatives: Tereos is integrating sustainable raw‑material sourcing and has a goal of zero waste in its production plants by 2035.

• Development of eco‑friendly production processes
• Strategic collaborations with European formula manufacturers
• Launch of premium infant formulas in the EU

9. ZuChem Inc.

Headquarters: San Diego, California, USA
Key Offering: Enzymatic synthesis of GOS and FOS for infant nutrition
Product Overview: ZuChem’s enzymatic platforms deliver high‑purity oligosaccharides with lower environmental impact.

Sustainability & Growth Initiatives: The company is scaling its enzyme production and exploring bio‑based raw materials.

• Low‑energy enzymatic processes
• Partnerships with global formula manufacturers
• Expansion into Latin America and Asia‑Pacific

10. Elicityl SA

Headquarters: Paris, France
Key Offering: GOS and FOS blends for infant nutrition and medical foods
Product Overview: Elicityl’s high‑purity oligosaccharides support infant gut health and are used in premium infant formulas.

Sustainability & Growth Initiatives: Elicityl is focusing on renewable energy integration and carbon‑neutral production by 2035.

• Innovation in GOS synthesis
• Strategic alliances with European formula manufacturers
• Growth in emerging markets through local partnerships

Download FREE Sample Report: Global Oligosaccharides in Infant Nutrition Market – View in Detailed Research Report

Get Full Report: Global Oligosaccharides in Infant Nutrition Market – View in Detailed Research Report

🌍 Outlook: The Future of Oligosaccharides in Infant Nutrition

The oligosaccharides market is poised for continued growth driven by increasing consumer awareness of gut health benefits, regulatory support for HMO‑fortified products, and advances in fermentation and enzymatic technologies. Key drivers include the expansion of premium infant formulas in emerging economies, the rise of personalized nutrition, and the integration of oligosaccharides into non‑formula products such as functional beverages and supplements.

📈 Key Trends Shaping the Market:

• Rapid adoption of HMOs in infant formulas across North America, Europe, and Asia‑Pacific.
• Regulatory incentives for clinical validation of gut‑health claims.
• Growth in direct‑to‑consumer models enabling customized oligosaccharide blends.
• Investment in sustainable, low‑energy production processes.
• Expansion of premium infant nutrition into emerging markets such as India, Indonesia, and Brazil.

🔮 Future Trends

1️⃣ Personalized Infant Nutrition – Advances in microbiome analytics will enable tailored oligosaccharide formulations for specific infant needs, creating niche premium products.

2️⃣ Synthetic Biology & Cost‑Effective Production – Engineered microbial strains will reduce production costs, making high‑purity oligosaccharides accessible to price‑sensitive markets.

3️⃣ Expansion into Functional Beverages & Supplements – Non‑formula applications will broaden market reach and provide convenient options for parents.

4️⃣ Regulatory Harmonization – Global alignment of safety and efficacy standards will accelerate market entry and reduce compliance costs.

5️⃣ Digital Health Integration – Mobile health platforms will support real‑time monitoring of infant nutrition outcomes, driving demand for data‑driven oligosaccharide products.